Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study [Phase 1]
Phase 1 RADIODOSE study assessing radiation dosimetry, safety, and tolerability of extended Lutetium-177 Vipivotide Tetraxetan in chemo-naïv…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer [NA]
This clinical trial update describes evaluating intrinsic validity of molecular marker detection in tumoral DNA to predict the efficacy of L…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc [Phase 2]
A randomized Phase II trial is evaluating targeted radiation without castration for metastatic castration-resistant prostate cancer, and the…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer [Phase 2]
This Phase 2 trial compares dapagliflozin plus a next-generation hormonal agent versus a single hormonal agent in metastatic castration-resi…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Clinical trial update for two PSMA-targeted radiopharmaceuticals (68Ga-PSMA-0057 and 177Lu-PSMA-0057) being studied for PSMA-positive metast…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
This clinical trial update describes a prospective study evaluating imaging response biomarkers during [177Lu]Lu-PSMA therapy in metastatic …
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
Real-world clinical study evaluating outcomes for metastatic castration-resistant prostate cancer patients treated with the olaparib and abi…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity [NA]
This clinical trial update describes a study using four-timepoint multi-tracer PET imaging to characterize heterogeneity in metastatic castr…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer [Phase 2]
This Phase 2 trial evaluates cabazitaxel, carboplatin, and cetrelimab with or without niraparib for aggressive variant metastatic prostate c…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. [Phase 2]
Phase 2 clinical trial assessing detection of metastases using PyL PET/CT in patients starting enzalutamide for untreated castration-resista…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer [Phase 1]
An ongoing Phase 1 trial evaluating Ac-225-PSMA-62 for oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: TmPSMA-02 in mCRPC [Phase 1]
This update indicates a Phase 1 clinical trial of TmPSMA-02 for metastatic castration-resistant prostate cancer is currently recruiting at t…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating oral HP518 in metastatic castration-resistant prostate cancer to assess safety, pharmacokinetics, and …
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer [Phase 2]
This update describes a Phase 2 clinical trial evaluating SX-682 in combination with enzalutamide for ARPI-resistant metastatic castration-r…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 2]
A phase 2 study of galunisertib in combination with enzalutamide for metastatic castration-resistant prostate cancer; the trial is currently…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of INV-9956 in adults with m…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating XL092 in metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer [EARLY_Phase 1]
The document reports an early-phase trial of adaptive Abiraterone therapy for metastatic castration-resistant prostate cancer and notes the …
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer [EARLY_Phase 1]
An early-phase study evaluating the safety and preliminary efficacy of combining an anti-IGF-1R monoclonal antibody with an anti-PD-1 monocl…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC [Phase 1, Phase 2]
Clinical trial update for ONC-392 in combination with Lutetium-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer …
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion [Phase 2]
A Phase 2 clinical trial is evaluating bortezomib in patients with metastatic castration-resistant prostate cancer with PTEN deletion; recru…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of fasudil hydrochloride in combination with immunotherapy for metastatic cas…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Combination Study of Antibiotics With Enzalutamide (PROMIZE) [Phase 1, Phase 2]
Clinical trial update for the PROMIZE study evaluating a combination of antibiotics with enzalutamide in metastatic castration-resistant pro…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 study assessing Lutetium-177-DGUL in combination with Pembrolizumab for metastatic castration-resistant prostate cancer; the trial s…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer [EARLY_Phase 1]
This early-phase clinical trial updates on the safety and efficacy of locally injected ACT#001 CAR-T cells for castration-resistant prostate…